Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
HCA (HCA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
HCA Healthcare has consistently outperformed the S&P 500, with shares up 43.8% since April 2023 and 66.8% since August 2021. Despite a decline in net income due to asset sales and rising interest expenses, other profitability metrics like operating cash flow and EBITDA have improved. Management's guidance for 2024 anticipates significant revenue and net income growth, with expected revenue between $69.75 billion and $71.75 billion.
The U.S. hospital industry has been flying high in the past year. Three hospital stocks to buy are: HCA, THC, UHS.
HCA (HCA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
HCA Healthcare (HCA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
HCA benefits from expanding insurance coverage, rising demand and improving margins.
Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. HCA, HUBB, RACE and VERX are some stocks that hold promise.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here is how HCA Healthcare (HCA) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.